Response to: 'Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudis et al

Ann Rheum Dis. 2022 May;81(5):e74. doi: 10.1136/annrheumdis-2020-217802. Epub 2020 May 20.

Tine Iskov Kopp¹, Bénédicte Delcoigne², Elizabeth V Arkema², Melinda Magyari^{3

4}, Henning Locht⁵, Finn Thorup Sellebjerg⁴, Rene Lindholm Cordtz⁶, Dorte V Jensen⁶, Johan Askling^{2

7}, Lene Dreyer^{8

9}

¹ The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark tine.iskov.kopp@regionh.dk.
² Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
³ The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
⁴ Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
⁵ Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark.
⁶ Center for Rheumatology and Spine Diseases - Gentofte, Rigshospitalet, Hellerup, Denmark.
⁷ Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
⁸ Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
⁹ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

No abstract available

Keywords: arthritis, psoriatic; arthritis, rheumatoid; epidemiology; spondylitis, ankylosing; tumor necrosis factor inhibitors.

Publication types